Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 17,922	$ 27,202	$ 61,312	$ 70,110
General and administrative	7,572	7,840	19,897	26,342
Legal expense	4,127		4,127
Total operating expenses	29,621	35,042	85,336	96,452
Loss from operations	(29,621)	(35,042)	(85,336)	(96,452)
Grant income				157
Other income, net	880	2,072	3,399	5,908
Net loss	(28,741)	(32,970)	(81,937)	(90,387)
Unrealized gain on available-for-sale securities	41	261	352	1,278
Comprehensive loss attributable to common stockholders	$ (28,700)	$ (32,709)	$ (81,585)	$ (89,109)
Net loss per share attributable to common stockholders, basic	$ (0.75)	$ (0.87)	$ (2.13)	$ (2.38)
Net loss per share attributable to common stockholders, diluted	$ (0.75)	$ (0.87)	$ (2.13)	$ (2.38)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	38,517,602	38,054,583	38,406,709	37,993,002
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	38,517,602	38,054,583	38,406,709	37,993,002